We examined serum bilirubin and various liver-function enzymes as possible riskfactors for angiographicallydocumented coronary artery disease (CAD). The studies involved a "training" set of 619 men for whom complete data on all risk factors considered were available, and a "test" set of 258 men for whom some riskfactor data were not available. In both study groups, the liver enzymes were not related to CAD; however, ln[total bilirubini was inversely and statistically significantlyrelated to the presence of CAD, both univariately and multivariately after adjustment for the established risk factors of age, total cholesterol, high-density lipoprotein cholesterol, smoking history, and systolic blood pressure. A 50% decrease in total bilirubin was associated with a 47% increase in the odds of being in a more severe CAD category. Our data suggest that serum bilirubin is an inverse and independent risk factor for CAD, with an association equivalent in degree to that of systolic blood pressure. 
Indexing Terms: antioxidants/risk factors/cholesterol/llpoproteins/ IWer-function enzymes
Lipids and lipoproteins are important risk factors for coronary artery disease (CAD); however, they do not account for disease in 30-40% of the population with CAD.3 To further improve our ability to predict CAD, we examined several nonlipid factors as possible risk factors. In preliminary studies, we found that serum bilirubin concentrations were decreased in individuals with CAD, whereas some of the liver-function enzyme activities were increased. Because decreased bilirubin concentrations and increased enzyme activities had not been previously associated with CAD, we sought to determine whether such associations existed in larger patient populations.
It is not known whether bilirubin has a role in preventing CAD; however, it could be involved in CAD in several ways. Bilirubin is a naturally occurring antiox- From the variables selected, a submodel including those variables for which the remaining 258 patients had complete data was tested.
Materials and Methods Subjects
Selection of variables was also examined on the training set of 619 by linear regression, with maximum percentage of obstruction as a continuous dependent variable, by using SAS PROC RSQUARE.
In addition, the Mantel-Haenszel odds ratio for association between CAD (severe vs mild or none) and total bilirubin (<10 vs 10 mo1/L), adjusted for other categorized covariates, was estimated by using SAS PROC FREQ.
Resufts Patient Groupsand Angiographic Data
Summary statistics for the two groups are given in Table 1 . In the training group of 619 patients, 111 (18%) had severe CAD, 87 (14%) had mild disease, and 421 (68%) were free of CAD. In the test group of 258 subjects, 35 (14%) had severe CAD, 47 (18%) had mild disease, and 176 (68%) had no CAD. Table 2 shows summary statistics by severity of CAD for the training group.
Logistic Regression Models
The results of the univariate and multivariate logistic regression modeling on the training set of 619 subjects are shown in Concerned that the observed association might be due to outliers in the data, we performed logistic regressions on mutually exclusive subsets of subjects, balanced with respect to CAD prevalence and to levels of the covariates. The standardized estimates of regression parameters from these analyses are shown in TableS. Consistency across the subsets was sufficient to indicate that the inverse association between CAD and total bilirubin was pervasive in our data set. Not only do the signs of the regression coefficients for ln[total bilirubin] tend to point in the same direction, but also, because the independent variables are standardized to means of 0 and standard deviations of 1, the strength of the association relative to the other risk variables can be assessed. In our data set, the association between CAD and total bilirubin was about the same as between CAD and either smoking (as measured by cigarettes per day) or systolic blood pressure.
Concerned that increased total bilirubin might indicate a liver disease, which somehow protected against CAl), we compared subjects in the "normal" subsets, who had all liver-function tests in the healthy ranges, with "abnormal" subjects, who had at least one abnormal liver-function test result. The healthy ranges were:
2-18 mol/L for total bilirubin, 
Other Modeling Approaches
Concerned that our arbitrary trifurcation of CAD into three categories might be too broad, we reanalyzed the training set of 619 subjects, using linear regression. Tot 611, total blllrubin; other abbreviationsas In Table 1 . Ten subsets were balancedon CAD prevalence and level of risk factors by first sorting the 819 by CAD severity (none, mild, severe) as the "outslde' sort and on the first principalcomponentof the six standardized rIsk factors as the "inside" sort. Evejy 10th subject in the sorted lIstwas then assignedto the same subset All risk factors were restandardizedto mean =0 and SD = 1 within each subset before logistic regressions. 5,6 ). Each of these fractions will need to be analyzed to determine which is most associated with CAD. We also think that the accuracy and precision of methods used to determine serum bilirubin will need to be improved if it, or its subfractions, are to be predictive for CAD.
This study did not include women or older men. It did not include young adult men with diabetes, obesity, or other chronic diseases.
It remains to be seen whether serum bilirubin is inversely associated with CAD in these groups. This was a cross-sectional prevalence study. A prospective study is needed to determine whether serum bilirubin helps predict future coronary heart disease. The selection process used in this study was also different from those used in other angiographic studies. For instance, the prevalence of disease in our study group was <18%, whereas the prevalence in other angiographic studies is generally >70%. We do not know if increased serum bilirubin prevents CAD, if CAD decreases serum bilirubin, or if serum bilirubin is an index of some factor in the pathogenesis of CAD. Bilirubin is, however, an effective antioxidant (1,2), possibly protecting lipids and lipoproteins against oxidation (3) and against plaque formation in humans (4). We also do not know why bilirubin concentrations are lower in individuals with CAD than in those without CAD. Perhaps this reflects an increase in oxidant activity or increases in iron stores (9) .
It remains to be seen whether abstinence from alcohol is related to low bilirubin concentrations. However, no association between increased consumption of alcohol and increased concentrations of bilirubin has been found (10). Bilirubin is also effective in the solubilization of cholesterol and in aiding in its clearance through the bile (5,6). Further studies are needed to confirm the association between bilirubin and CAD in independent populations and to elucidate the various pathogenic mechanisms involved.
